How to train your T cell: Genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia

Expert Opinion on Biological Therapy

Volumn 15, Issue 6, 2015, Pages 761-766

  Ruella, Marco ^a,b   Gill, Saar ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Adoptive cell therapy; B cell acute lymphoblastic leukemia; Bispecific T cell engager; Blinatumomab; CART19; CD19; Chimeric antigen receptor; CTL019; Immunotherapy; Lymphoma; Non Hodgkin lymphoma

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGER; BLINATUMOMAB; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TISAGENLECLEUCEL T; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHIMERA; CONTINUOUS INFUSION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR IMMUNOLOGY; COMPARATIVE STUDY; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROTEIN ENGINEERING; T LYMPHOCYTE; TRENDS;

ANTIGENS, CD19; CHIMERA; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84929907293     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1009888     Document Type: Review

References (27)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342(6165):1432-3
2. Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med 2014;65:185-202
3. Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev 2014;257(1):14-38
4. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371(16):1507-17
5. Topp MS, Gokbuget N, Zugmaier G, et al. Phase II Trial of the anti-CD19 Bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic Leukemia. J Clin Oncol 2014;32(36):4134-40
6. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19- 28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med 2014;6(224):224ra25
7. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2014; [Epub ahead of print]
8. Loffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95(6):2098-103
9. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8
10. Topp MS, Gokbuget N, Zugmaier G, et al. Long-Term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7
11. Goekbuget N, Bonifacio M, Reichle A, et al. BLAST: a confirmatory, single-Arm, Phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE-) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #379
12. Goekbuget N, Bruggemann M, Stein A, et al. An evaluation of molecular response in a Phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) receiving treatment with the BiTE- antibody construct blinatumomab. Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #3704
13. Zugmaier G, Viardot A, Stelljes M, et al. Long-Term survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) who achieved minimal residual disease (MRD) response following anti-CD19 BiTE- blinatumomab. Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #2287
14. Arend von Stackelberg A, Zugmaier G, Handgretinger R, et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #2292
15. Gore L, Zugmaier G, Zwaan CM, et al. Initial results from a Phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #3703
16. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121(26):5154-7
17. Schub A, Zugmaier G, Brandl C, et al. Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Am Soc Clin Oncol (ASCO) Ann Meeting 2013;31(Suppl 18):abstract #7020
18. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-Type specificity. Proc Natl Acad Sci USA 1989;86(24):10024-8
19. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17(8):1453-64
20. Kenderian SS, Ruella M, Gill S, et al. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 2014;74(22):6383-9
21. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73
22. Frey NV, Lacey SF, Grupp SA, et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #2296
23. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73
24. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124(2):188-95
25. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18
26. Duell J, Bedke T, Mueller T, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Am Soc Hematol Ann (ASH) Meeting 2014;124(21):abstract #2291
27. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4(132):132ra53